Phathom Pharmaceuticals (NASDAQ:PHAT) Receives Sell (D-) Rating from Weiss Ratings

Phathom Pharmaceuticals (NASDAQ:PHAT)‘s stock had its “sell (d-)” rating reissued by research analysts at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Phathom Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Phathom Pharmaceuticals Price Performance

Shares of PHAT opened at $13.53 on Friday. The business’s fifty day moving average price is $12.04 and its 200 day moving average price is $8.64. Phathom Pharmaceuticals has a 12-month low of $2.21 and a 12-month high of $19.50. The stock has a market capitalization of $959.82 million, a PE ratio of -2.86 and a beta of 0.43.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in Phathom Pharmaceuticals in the 2nd quarter worth about $30,000. Ameritas Investment Partners Inc. increased its stake in Phathom Pharmaceuticals by 39.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock worth $41,000 after purchasing an additional 1,216 shares in the last quarter. CWM LLC increased its stake in Phathom Pharmaceuticals by 20,997.1% in the 1st quarter. CWM LLC now owns 7,384 shares of the company’s stock worth $46,000 after purchasing an additional 7,349 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Phathom Pharmaceuticals by 71.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company’s stock worth $49,000 after purchasing an additional 2,122 shares in the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Phathom Pharmaceuticals by 58.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock worth $55,000 after purchasing an additional 2,102 shares in the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.